Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well ...
Source LinkRecursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well ...
Source Link
Comments